inflect1on
Posted - 11 hours ago
$PAVM please divest $LUCD so we can finally be rid of the tumor that is pavm mgmt
LetsMakeM0n3y
Posted - 13 hours ago
$PAVM $LUCD IMAGINE, they gave you worthless shares of LUCD. What a garbage company. And then they have the audacity to say they can just "turn it on".
LetsMakeM0n3y
Posted - 13 hours ago
$PAVM $LUCD looks like @LPlates was right again.
oaksapollo
Posted - 14 hours ago
$LUCD The pressure from the convertible just never lets up. We need news on coverage asap, or we'll be looking at a reverse split.
Grumpy56
Posted - 17 hours ago
@GreatHobby Completely disagree with your analysis, why? Because $LUCD is a medical diagnosis company and has nothing to do with the value of EV’s.
GreatHobby
Posted - 1 day ago
$NKLA is being dragged through the mud thanks to $TSLA $LUCD & $LI EV Sales & Price Cuts Nikola's CEO Girsky specifically said to the reporter on Fox Business News that NIKOLA is actually Selling Every Truck they Build & Raising Prices!!!
oaksapollo
Posted - 3 days ago
$LUCD the NYT Wordle today was ”Lucid.” I think it’s a sign things are about to turn around
Bears_VS_Bulls_
Posted - 3 days ago
$MULN $NKLA $RIVN $LUCD $FSRN and others ... All EV sector is scam . Down 85 / 90% or even 95% from its first trading day . So sorry for bag holders .
intratio
Posted - 4 days ago
$LUCD https://www.intratio.com/stock-forecast/LUCD The engine is predicting this equity s value will increase soon and is neither a long or short opportunity in the longer term
RetiredMD
Posted - 4 days ago
$LUCD All interested parties moving forward should be focused on the MolDX and TA process to get Medicare coverage for LUCD. Can someone that is more familiar with this process chime in on exactly how this process works with a timeline. I have found this in my research... https://www.youtube.com/watch?v=CzBRh2LIZ1I Thanks!
oaksapollo
Posted - 4 days ago
$LUCD did anyone read the proxy? There’s a few little interesting bits in there.
LetsMakeM0n3y
Posted - 4 days ago
$LUCD $PAVM bagholders galore. What say you, @LishanAklogMD? You're the biggest bagholder of them all.
Seanwishwise
Posted - 5 days ago
$NIO $LUCD $VFS all ev rebound. 👀🤞
oaksapollo
Posted - 6 days ago
$LUCD @LishanAklogMD you sold this stock to investors for $14/share. If you really believe in this technology, how can you not buy at a 95% discount to IPO price?! I hope we see some Form 4s soon (or some type of material news that finally turns this around).
LPlates
Posted - 1 week ago
@Ironbow @RetiredMD The only difference between you and me is I have been right all along since $9+ and you have been wrong. Why don't you come up with a projection of how $PAVM can fund itself and or $LUCD , while losing in REAL cash $6m a quarter. Lishan, Dennis etc can say pretty much anything in Events, and fireside chats. But say them in an SEC filing and they go to jail. So SEC filings are the truth, without spin. So please layout how $PAVM &$lucd can find themselves and how much would they need to raise? It's really REALLY ugly.
inflect1on
Posted - 1 week ago
$LUCD after nearly 2 years.. it may be time to give this another look (are we still attached to that pavm tumor)
LPlates
Posted - 1 week ago
@RetiredMD I think EsoCheck is by far the best cell collection device. No disagreement there. But... The vast majority of people that will test will not be interested in what is the device and it's strengths and weaknesses. To try and educate them it would take years and $10's of millions You miss my point. It's not who has the best technology. It's who can get people "at risk" to take their test. EXAS with ColoGuard has vast customer databases of people who trust their test and brand. There is a correlation between colorectal and esophageal cancer. So it's easy for EXAS to do a mailing to all their customers, who need to be screened this year, offering a ColoGuard test plus a coupon for their esophageal test for $100 more than Cologuard alone.
Without any money $LUCD had be sold after Ayrton restructures it to EXAS as no large company can compete going DTC with EXAS. It's all in the 10k's.
LPlates
Posted - 1 week ago
@Ironbow @oaksapollo So you don't disagree that $LUCD and $PAVM will run out of money by the end of the summer? So that means you lied when you said that the $18m that LUCD raised means there will be no more raises. Because PAVM and LUCD need approximately $18m every quarter as they burn that in real cash. You don't (can not) disagree that PAVM can NOT raise anymore money as PAVM along with a going concern warning said they are not able to raise any more money and need to be funded by LUCD in Marchs 10k.
oaksapollo
Posted - 1 week ago
$LUCD can everyone just put @LPlates on ignore? He ran out of new things to say a year ago. All he does now is disrupt every thread.
LPlates
Posted - 1 week ago
@RetiredMD Another Dr. on here agreed that part of ColoGuards success was the alternative of a Colonoscopy motivated men to use ColoGuard instead. He also said that the same motivational factors don't exist for EsoGuard. The article on the CEO of EXAS that turned EXAS around is a good read. It's his Sales and Marketing background that allowed them to succeed. EXAS was floundering much like $PAVM and $LUCD until Kevin Conroy joined. So there are two parts. The test. But even more importantly is the ability to market that test to consumers. Direct to consumer marketing is as hard as creating EsoGuard and EsoCheck. But it also costs VASTLY more money in the order of losing an additional $50m a year for 5 years to create a brand that is both known and trusted. Lishan and Dennis have failed 5 times to successfully launch a product. Not a single success. And they have no money and no possibility of getting more $$. FACTS
RetiredMD
Posted - 1 week ago
$LUCD Reasons to be Bullish on LUCD: 1. FDA Clearance since 2019 2. A technology that has proven to be both safe and efficacious over a wide (and ever expanding) number of studies. 3. Intellectual Property that is protected and superior and any competition in both the short and mid term. 4. Technology that has been accepted and recommended by both of the leading G.I. associations in the United States. 5. Addresses an unmet need for the SECOND most deadly cancer in the United States. 6. Huge market potential...60+ million Americans have GERD. This is not taking into consideration that in the mid to long term EsoCheck could be recommended to everyone of a certain age (Pap smear/colonoscopy). 7. The direct to consumer (DTC) marketing for Freddy the Food Tube for people with chronic heartburn would be way more potent then Cologaurd's box mascot for colon cancer.
Supbe
Posted - 1 week ago
$LUCD pretty obvious short selling price manipulation. stay strong bulls. this is not an inferior product
dmc4321
Posted - 1 week ago
@Ironbow @LPlates @oaksapollo @PAVM_Millionaire Its not interpreting it when in the $PAVM 10K that was filed last month PAVM said "they can not raise money" and that they will require $LUCD or Veris to fund them going forward. That's not an interpretation. Thats what PAVM management said in the one medium (SEC filing of their 10K) where if they lie they go to jail. So that's where they must tell the truth in amongst hundreds of pages of filler.
dmc4321
Posted - 1 week ago
@PAVM_Millionaire @LPlates @oaksapollo @Ironbow My Ayrton assessment is correct. Ayrton have earned but have not been issued about 2X of the current supposed outstanding share count. When Ayrton has them issued they will have complete control of $PAVM and $LUCD Ayrton don't operate companies. Show me one example Ayrton was called a predatory lender for trying to get $200M for an $18M SPA just over a year ago. They settled immediately which suggests to me they did not want to disclose "things" in discovery. The same Dennis that told me that "We have studied the ColoGuard launch and while it was good they made mistakes". That one afther they have blown through circa $100M for less then $5M of revenue and test numbers are shockingly bad.
Jswizzle
Posted - 1 week ago
$PAVM $LUCD any guesses on when you personally think coverage is coming?
LPlates
Posted - 1 week ago
@oaksapollo that's a lie. $PAVM has control of $LUCD PAVM in it's recent 10k said they CAN NOT raise anymore $$'s and will need to be funded by LUCD or Veris. Obviously Veris has no $$, so it's down to LUCD. That $18m is enough cash to run the group for 3 months. The group, according to the 10k filed earlier this month, started 2024 with $20m and they lose about $6m a MONTH. So that $20m is gone. The $18m will be gone by end of July. So id LUCD have no money and PAVM has no money what can they do? RESTRUCTUTRE and Ayrton who has a stealth holding of about 70%+ of PAVM will decide what happens. But Ayrton only wants it's money back. Ayrton doesn't operate companies and as they effectively own both PAVM and LUCD they would be diluting themselves by investing anymore It's all in the 10k
dmc4321
Posted - 1 week ago
@drock123 I would have a different take from the fireside. To talk at such great length and specificity about a competitor reeks of fear to me. All along I have said the value is in EsoCheck not EsoGuard. The OncoGuard test, and EXAS, imo, will only launch it after there is full coverage in place, doesn't have to be as good or better than EsoGuard. All it needs if FDA approval. Most people dont know or have any interest in learning about the specificity of a test. They will recognize the ColoGuard brand and that will be enough. It would take $100's of millions to educate the average consumer. What wasnt addressed was both $PAVM and $LUCD running out of money this Summer. Remember the figures PAVM released included LUCD as they consolidate LUCD as a subsidiary. PAVM in the last 10K said they can not raise $$ and are dependent on LUCD to give them $$ to keep the lights on. Do the math as they both run out of $$ in the Summmerlast
oaksapollo
Posted - 1 week ago
$LUCD Continuing to add, I think in a few months we will look back and regret not buying more here. Just my opinion. If they had not just raised $18M, I would be much more hesitant, but the cash raise is off the table in the near term, seems like a great entry point with all the potential catalysts coming in the next year.
